Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CPT2 | P23786 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| .Beta.-Hydroxyisovaleric Acid SCHEMBL95499 | 0.91 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL29991820 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL2340215 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL30764122 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL31058606 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL925875 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL5159910 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL723161 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL10277346 | 0.88 | — | — | |
| .Beta.-Hydroxyisovaleric Acid SCHEMBL30764083 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342005-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| WO-2005056607-A1 | PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN | BELUPO-LIJEKOVI I KOZMETIKA D.D. (HR) | 2005-06-23 | — | — | WO | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0579826-B1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-4232164-A | Purification of AT-125 | THE UPJOHN COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4225720-A | Purification of AT-125 | THE UPJOHN COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| US-4188324-A | Purification of AT-125 | THE UPJOHN COMPANY (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | HMGCR 674/4885CHRM1 394/4885TBXA2R 4786/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | HMGCR 349/4885CHRM1 593/4885TBXA2R 4870/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | HMGCR 376/4885CHRM1 651/4885TBXA2R 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.